This article was updated on September 02, 2026 In December 2025, we asked our in-house team of experts how they expected to see the industry evolve over the coming year.
Germany’s Bundesrat voted on November 21 to support key restrictions on medical cannabis prescribing and distribution, while rejecting proposals to ban prescriptions being sent via mail, a mixed outcome that offers both relief and concern for an industry bracing for regulatory tightening.
Germany’s medical cannabis imports continued their historic run in Q3 of 2025, seeing the country bring in just under 57 tonnes, though growth levels dipped slightly from Q2.
Airo Brands, a US multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe and Australia.
Australia and Germany are moving in opposite directions on medical cannabis imports, as both scramble to deal with the runaway growth of their medical cannabis markets.
Synbiotic SE German cannabis and hemp group Synbiotic SE has issued a substantial downgrade to both its sales and profit forecasts for the full year 2025 as Germany’s rapidly inflated medical cannabis bubble shows the first signs it could be about to burst.
Telemedicine and access to medical cannabis via online platforms have become a central issue in Germany’s cannabis sector, drawing scrutiny from policymakers and healthcare professionals.
